|
Volumn 93, Issue 19, 2001, Pages 1437-1439
|
Future for ovarian cancer screening: Novel markers from emerging technologies of transcriptional profiling and proteomics
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CA 125 ANTIGEN;
CREATINE KINASE;
DNA;
MESSENGER RNA;
OSTEOPONTIN;
PROTEOME;
RNA;
SERINE PROTEINASE;
TUMOR MARKER;
BREAST CANCER;
CANCER CELL CULTURE;
CANCER LOCALIZATION;
CANCER SCREENING;
CANCER STAGING;
CANCER THERAPY;
CLINICAL EXAMINATION;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DNA HYBRIDIZATION;
EARLY DIAGNOSIS;
EDITORIAL;
FEMALE;
GENE EXPRESSION;
GENETIC TRANSCRIPTION;
HUMAN;
HUMAN CELL;
HUMAN TISSUE;
LAPAROSCOPY;
LAPAROTOMY;
MAMMOGRAPHY;
MASS SCREENING;
MASS SPECTROMETRY;
MEDICAL GENETICS;
OVARY CANCER;
PREDICTION;
PREVALENCE;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
SENSITIVITY AND SPECIFICITY;
TREATMENT OUTCOME;
TUMOR BIOPSY;
UTERINE TUBE CARCINOMA;
|
EID: 0035802226
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/93.19.1437 Document Type: Editorial |
Times cited : (63)
|
References (24)
|